Insider trade

CEO sold ~$551K of CYTK shares in the open market

Traded Sep 14, 2026 · Filed Sep 15, 2026

Why it stands out

The boss of Cytokinetics sold $551K of Cytokinetics shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$550,800

Shares × reported transaction price

Timing vs results

39 days after results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−5.2%	+1.8%	−7.0%

Past results only. Not a forecast.

Sale of shares of common stock acquired upon exercise of stock options. Transaction is pursuant to a trading plan adopted by the reporting person intended to satisfy the conditions of Rule 10b5-1(c).

yesterday

Derivative exercise or conversion — not an open-market buy.

Automatic saleyesterday

yesterday

Derivative exercise or conversion — not an open-market buy.